PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Eslicarbazepine acetate - Epilepsy
PAD Profile : Eslicarbazepine acetate - Epilepsy Important
Brand Names Include :
Zebinix
Important Information :
Only when 1st-line and 1st-line adjunctive agents have been unsuccessful
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Carbamazepine
- Clobazam
- Lacosamide
- Clonazepam
- Perampanel
- Ethosuximide
- Felbamate
- Rufinamide
- Gabapentin
- Stiripentol
- Lamotrigine
- Zonisamide
- Levetiracetam
- Oxcarbazepine
- Phenobarbital
- Piracetam
- Phenytoin
- Pregabalin
- Topiramate
- Sodium valproate
- Brivaracetam
- Sodium valproate
- Cannabidiol
- Vigabatrin
- Cenobamate
- Primidone
- Tiagabine
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (National)
01 April 2021
Shared Care
Eslicarbazepine for treatment of Adults with Focal Seizures - Shared Care Amber ESHUT - November 201
31 March 2020
Shared Care
31 March 2020
Committee Recommendations
Date
Committee Name
Narrative
20 February 2013
Epsom St Helier NDAIG
Shared care documentation approved
04 April 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN supported the principles of switching from brand to generic medications (not recommended in the elderly) as per national guidelines in September 2013 and the proposed place in therapy of the anti-epileptic drugs which is based on NICE guidance was also discussed at that time. Shared Care supported in November 2014 are attached below. Please note the MHRA categorisations for each drug in the attached guidance (updated January 2014) and in the link below.
Associated BNF Codes
04. Central Nervous System
04.08.01. Control of epilepsy